Suggestions
Dan Cowell
COO at Momentous Therapeutics
Dan Cowell is an experienced biotech executive currently serving as the Chief Operating Officer at Momentous Therapeutics Ltd.12 Here are some key details about his background and career:
Professional Experience
Dan Cowell has over 25 years of experience in the biotech industry, with a proven track record of managing and co-founding innovative companies.2 His career highlights include:
- Chief Operating Officer at Momentous Therapeutics Ltd (2022-present)13
- CEO of Psyomics Ltd (2015-2020)1
- Chief Operating Officer at Horizon Discovery (2010-2014)1
- Co-founder and CEO of Hypoxium (2008-2010)1
- Co-founder and Director of Pharmorphix (2003-2007)1
Education and Expertise
Dan Cowell holds a Bachelor of Science degree in Chemistry from the University of Kent.1 His areas of expertise include:
- Drug discovery and development
- Biotechnology
- Cell biology
- Oncology
- Genomics
- Research and development
Board Positions
In addition to his executive roles, Dan has served on several boards:
- Non-Executive Director at Sentinel Oncology since 20112
- Non-Executive Director at Techspert.io (2016-2020)1
- Non-Executive Director at Euprotec Ltd (2010-2014)1
Entrepreneurial Background
Dan Cowell has a strong entrepreneurial background, having:
- Co-founded and managed multiple biotech companies
- Taken three research services companies from foundation to exit
- Led a gene editing company from start-up to IPO as COO
- Co-founded and managed a digital mental health diagnostics platform2
Current Role at Momentous Therapeutics
As the Chief Operating Officer at Momentous Therapeutics Ltd, Dan Cowell is part of the leadership team driving the company's mission in biotechnology research and development.34 His extensive experience in drug discovery and company management makes him well-suited for this role in an innovative therapeutics company.
Highlights
Can anyone in my network recommend someone for a part-time/ consulting CFO role? I'm working with two companies with a need in this area. One at pre-seed stage in drug discovery and one in drug discovery heading towards Phase I. Both exciting companies!
Congratulations to Graham Mills, PhD, Dave Holden-White and the team at techspert.io on their raise of $12m led by BGF and Nauta Capital Since experiencing the pain points and inefficiencies first hand while trying connect to experts in the healthcare sector - they have gone on to create a platform that goes way beyond their initial challenge. By applying AI and machine learning they have redefined how we can index and access over 200 million experts worldwide, covering millions of expertise areas. This round is another great milestone, validating their technical, commercial and real world use of AI/ machine learning to address the problem of the intensive human capital that is required in the traditional search process.
